Use of the levonorgestrel-releasing intrauterine device for the symptomatic treatment of uterine myomas

Silva, J. C. Rosa e; Silva, A. C. J. S. Rosa e; Reis, Francisco José Candido dos; Manetta, Luiz Alberto; Ferriani, Rui Alberto; Nogueira, Antônio Alberto

doi:10.1016/j.ics.2004.05.110

Cited by 9 publications

(15 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The reported LNG-IUS expulsion rates among women with uterine leiomyomas range between 0% and 20%, and are higher than those without uterine leiomyoma (0% to 3%). Also, significantly higher rates of expulsion have been noted among women with greater uterine volumes (a possible proxy for fibroid size) than among those with smaller ones [36-39,45,46]. …”

Section: Leiomyomamentioning

confidence: 99%

Clinical applications of levonorgestrel-releasing intrauterine system to gynecologic diseases

Kim

Seong

2013

Obstet Gynecol Sci

View full text Add to dashboard Cite

The levonorgestrel-releasing intrauterine system (LNG-IUS), originally designed for contraception, has since been applied to various gynecologic diseases. This article summarizes the current status of clinical applications of LNG-IUS to the treatment of gynecologic diseases such as heavy menstrual bleeding, endometriosis, leiomyoma, adenomyosis, endometrial hyperplasia, and early-stage endometrial cancer.

show abstract

Section: Leiomyomamentioning

confidence: 99%

Clinical applications of levonorgestrel-releasing intrauterine system to gynecologic diseases

Kim

Seong

2013

Obstet Gynecol Sci

View full text Add to dashboard Cite

show abstract

“…Use of the LNG‐IUS leads to a reduction in MBL shortly after insertion because of its antiproliferative action on the endometrium [7]. Previous studies have shown a reduction in MBL and a significant improvement in anemia in users of the LNG‐IUS, particularly in cases of anemia caused by menorrhagia [3,8–11]. Therefore, this system is now used in the treatment of idiopathic menorrhagia [11–13].…”

Section: Introductionmentioning

confidence: 99%

Efficacy of the levonorgestrel‐releasing intrauterine system in uterine leiomyoma

Kriplani

Awasthi

Kulshrestha

et al. 2011

Intl J Gynecology & Obste

View full text Add to dashboard Cite

show abstract

“…Expulsion rates are directly proportional to uterine volume 23 and can be as high as 20%. 24,25 Gonadotrophin-releasing hormone (GnRH) analogues have also been used in the medical management of uterine fibroids and have been shown to reduce the size of fibroids and ameliorate symptoms particularly before surgery. However, due to their side effects, which include menopausal symptoms and osteoporosis, their use is limited.…”

Section: Current Medical Managementmentioning

confidence: 99%

Is ulipristal acetate the new drug of choice for the medical management of uterine fibroids? Res ipsa loquitur?

Odejinmi

Oliver

Mallick

2017

Womens Health (Lond Engl)

View full text Add to dashboard Cite

Ulipristal acetate (Esmya © ) has been hailed the new wonder drug with regard to the medical management of uterine fibroids, and many postulate that it will remove the need for surgical treatment in the future. While the results from the PEARL studies are certainly promising and its amenorrhoeic rates and reduction in fibroid size are unquestionable, there is still a paucity of data with regard to its long-term effects, the effects on its usage prior to surgery and its variable efficacy in different ethnic populations. To facilitate our knowledge further, independent studies with clear outcome measures evaluating the long-term effects of the drug in a wider, more representative, ethnic minority population as well as assessing its true cost-effectiveness compared to surgery are needed. The aim of this article is to review the historical aspects with regard to the management of uterine fibroids to gain an understanding of where we are now and to evaluate the wider use of ulipristal acetate, both its benefits and limitations and postulate where to go in the future in order to allow our women to make safe and informed choices regarding their treatment options.

show abstract

Use of the levonorgestrel-releasing intrauterine device for the symptomatic treatment of uterine myomas

Cited by 9 publications

References 12 publications

Clinical applications of levonorgestrel-releasing intrauterine system to gynecologic diseases

Clinical applications of levonorgestrel-releasing intrauterine system to gynecologic diseases

Efficacy of the levonorgestrel‐releasing intrauterine system in uterine leiomyoma

Is ulipristal acetate the new drug of choice for the medical management of uterine fibroids? Res ipsa loquitur?

Contact Info

Product

Resources

About